{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:49:09Z","timestamp":1784836149186,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00415-023-11788-x","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:02:18Z","timestamp":1684846938000},"page":"4377-4384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Could efficacy at 1\u00a0week after galcanezumab administration for patients with migraine predict responders at 3\u00a0months? A real world study"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-8993","authenticated-orcid":false,"given":"Keisuke","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"11788_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"11788_CR2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1212\/WNL.0000000000200899","volume":"99","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, Velez C, Ramajo AP, Abdrabboh A, Xu C, Rasmussen S, Tepper SJ (2022) Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine-clinical considerations: a narrative review. Neurology 99:841\u2013853","journal-title":"Neurology"},{"key":"11788_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21:284\u2013294","journal-title":"Lancet Neurol"},{"key":"11788_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"S American Headache","year":"2019","unstructured":"American Headache S (2019) The American headache society position statement on integrating new migraine treatments into clinical practice. Headache 59:1\u201318","journal-title":"Headache"},{"key":"11788_CR5","doi-asserted-by":"publisher","unstructured":"Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S, Italian Migraine Registry Study G (2023) Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000207292","DOI":"10.1212\/WNL.0000000000207292"},{"key":"11788_CR6","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211\u2013e2221","journal-title":"Neurology"},{"key":"11788_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, Ashina M, van den Maagdenberg A, Dodick DW (2022) Migraine. Nat Rev Dis Primers 8:2","journal-title":"Nat Rev Dis Primers"},{"key":"11788_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S Forderreuther","year":"2018","unstructured":"Forderreuther S, Zhang Q, Stauffer VL, Aurora SK, Lainez MJA (2018) Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain 19:121","journal-title":"J Headache Pain"},{"key":"11788_CR9","doi-asserted-by":"publisher","unstructured":"Garate G, Gonzalez-Quintanilla V, Gonzalez A, Pascual M, Perez-Pereda S, Madera J, Pascual J (2023) Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol https:\/\/doi.org\/10.1002\/ana.26658","DOI":"10.1002\/ana.26658"},{"key":"11788_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/jnnp-2018-320242","volume":"90","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK (2019) Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 90:939\u2013944","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11788_CR11","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.2147\/JPR.S326905","volume":"14","author":"H Igarashi","year":"2021","unstructured":"Igarashi H, Shibata M, Ozeki A, Day KA, Matsumura T (2021) Early onset and maintenance effect of galcanezumab in Japanese patients with episodic migraine. J Pain Res 14:3555\u20133564","journal-title":"J Pain Res"},{"key":"11788_CR12","doi-asserted-by":"publisher","first-page":"15439","DOI":"10.1523\/JNEUROSCI.3265-12.2012","volume":"32","author":"EA Kaiser","year":"2012","unstructured":"Kaiser EA, Kuburas A, Recober A, Russo AF (2012) Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT(1B\/D) agonist. J Neurosci 32:15439\u201315449","journal-title":"J Neurosci"},{"key":"11788_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton DL (2019) A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 39:1284\u20131297","journal-title":"Cephalalgia"},{"key":"11788_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ (2022) Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia 42:705\u2013714","journal-title":"Cephalalgia"},{"key":"11788_CR15","doi-asserted-by":"publisher","unstructured":"Lee HC, Cho S, Kim BK (2023) Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. Neurol Sci https:\/\/doi.org\/10.1007\/s10072-023-06683-2","DOI":"10.1007\/s10072-023-06683-2"},{"key":"11788_CR16","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1007\/s12325-021-01708-8","volume":"38","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Samaan KH, Schwedt TJ, Nicholson RA, Rettiganti M, Pearlman EM (2021) Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis. Adv Ther 38:3154\u20133165","journal-title":"Adv Ther"},{"key":"11788_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain 23:67","journal-title":"J Headache Pain"},{"key":"11788_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s10194-021-01230-w","volume":"22","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E (2021) Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 22:15","journal-title":"J Headache Pain"},{"key":"11788_CR19","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38:1442\u20131454","journal-title":"Cephalalgia"},{"key":"11788_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75:1080\u20131088","journal-title":"JAMA Neurol"},{"key":"11788_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, Iba C, Shibata M, Takemura R, Hori S, Nakahara J (2022) Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22:512","journal-title":"BMC Neurol"},{"key":"11788_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ene.15563","volume":"30","author":"F Vernieri","year":"2023","unstructured":"Vernieri F, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Rao R, d\u2019Onofrio L, Finocchi C, Aguggia M, Bono F, Ranieri A, Albanese M, Di Piero V, Cevoli S, Altamura C, Barbanti P, Group GS (2023) Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: the multicenter prospective cohort GARLIT study. Eur J Neurol 30:224\u2013234","journal-title":"Eur J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11788-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11788-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11788-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T20:05:53Z","timestamp":1702497953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11788-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["11788"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11788-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. K. Suzuki received lecture fees from Eli Lilly Japan, Daiichi Sankyo and Otsuka Pharmaceutical Co., Ltd., during the conduct of the study. S. Suzuki received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen and Otsuka Pharmaceutical Co., Ltd., during the conduct of the study. T. Shiina received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen and Otsuka Pharmaceutical Co., Ltd., during the conduct of the study. Y. Haruyama, H. Fujita and K. Funakoshi have nothing to disclose. K. Hirata received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen, Sawai Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki and was approved by the Institutional Review Board of the Dokkyo Medical University Hospital. The Institutional Review Board of the Dokkyo Medical University Hospital waived the need for patients to sign informed consent forms based on the retrospective, observational nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}